- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06093230
A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
An Open-label, Single-dose, Phase I Study to Assess the Pharmacokinetics and Safety of JT001 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Study Overview
Status
Intervention / Treatment
Detailed Description
This study adopts a non randomized, open, parallel controlled, single dose experimental design and is divided into three experimental groups: mild liver function impairment group (Group A), moderate liver function impairment group (Group B), and normal liver function subject group (Group C). Subjects in each experimental group took 0.3g of JT001 orally on an empty stomach and collected blood samples before and after administration for pharmacokinetic analysis.
After both groups A and B were enrolled, Group C subjects will be enrolled subsequently and should be matched with subjects with liver function impairment (Group A and Group B) as following:
The average body weight of Group C is within ± 10 kg of the average body weight of the group of subjects with liver function impairment (Groups A and B).
The average age of Group C is within ± 10 years of the average age of the group of subjects with liver function impairment (Groups A and B).
The number of subjects of each gender in Group C is similar to that in the liver function impairment group (A and B groups) (± 1 subject/gender).
The study is divided into three stages: screening period, baseline period, and experimental period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University Ethics Committee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- On the day of signing the informed consent form, the age range is 18 to 70 years (including both ends), both male and female are eligible;
Male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; Body mass index (BMI) 18-32 kg/m2 (including both ends), where BMI=weight (kg)/height 2 (m2);
Subjects with normal liver function also need to meet all the following conditions:
When screening, the following demographic matching criteria must be met:
- Match the weight with the liver function impairment group, with a mean of ± 10 kg;
- Age matched with the liver function impairment group, with a mean of ± 10 years;
- Gender matching was performed with the liver function impairment group, with a mean of ± 1 case;
Subjects with liver function impairment also need to meet all the following conditions:
- Patients with chronic liver injury caused by primary liver diseases (such as hepatitis B, hepatitis C, autoimmune hepatitis, alcoholic liver disease, etc.) and stable liver function (without any liver disease related medical records within 14 days before taking the study drug, except for regular follow-up and medication) with liver dysfunction classified as A or B by Child-Pugh ;
- Clinically diagnosed as liver cirrhosis;
- Those who have a stable medication plan for the treatment of liver function damage, complications, and other accompanying diseases for at least 14 days before taking the study drug, and the medication does not need to be adjusted (including medication type, dosage, or frequency); Or those who have not taken medication;
- Estimated Glomerular filtration rate (eGFR, calculated using the CKD-EPI formula) ≥ 60 mL/min/1.73m2;
Exclusion Criteria:
- The electrocardiogram shows a QTc interval (QTcF) of>450 msec for males and>470 msec for females (corrected according to Fridericia's standard);
- Screening for individuals with severe infections, trauma, gastrointestinal surgery, or other major surgical procedures within the first 4 weeks;
- Those who have received the vaccine within 14 days before screening or plan to receive the vaccine during the study period;
- Those who donate blood or have a blood loss of ≥ 400 mL within the first 3 months of screening, or intend to donate blood during or within 1 month after the trial;
- Screening for potent inhibitors or inducers of Pg-P or BCRP that have been used within the previous month (see Attachment 4);
- Those who have taken a special diet (including dragon fruit, mango, grapefruit, and/or xanthine diet, chocolate) and/or consumed excessive amounts of tea, coffee, grapefruit/grapefruit juice, and/or caffeinated beverages (an average of 8 or more cups per day, 200 mL per cup) within 2 weeks before administration;
- Screening for alcoholics within the first three months, i.e. those who consume more than 14 units of alcohol per week (1 unit=360 mL of beer, or 45 mL of 40% alcohol or 150 mL of wine) or those who are positive for alcohol screening;
Individuals who smoke an average of 10 or more cigarettes per day within the first 3 months of screening;
Subjects with normal liver function who meet any of the following exclusion criteria need to be excluded:
- History of liver injury;
- Individuals who have previously or currently suffered from any clinical serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, or any other diseases that may interfere with the test results;
- Abnormalities in physical examination, vital signs, laboratory examination, 12 lead electrocardiogram, abdominal ultrasound, and other examinations have been determined by the researcher to have clinical significance;
- Those who are positive in any index screening of hepatitis B surface antigen, hepatitis C antibody or hepatitis C core antigen, HIV antigen/antibody or syphilis antibody;
Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or supplements within 14 days prior to the administration of the study drug;
Subjects with liver function impairment who meet any of the following exclusion criteria need to be excluded:
- The subject has any of the following conditions: drug-induced liver injury; History of liver transplantation; And researchers believe that liver cirrhosis
- During screening, the laboratory test results meet any of the following criteria: (a) alanine aminotransferase (ALT) or aspartate aminotransferase (AST)>5 × ULN; (b) Absolute value of neutrophils (NE #)<1 × 109/L; (c) Hemoglobin (HGB)<80 g/L; (d) Alpha fetoprotein (AFP)>100 ng/mL;
- Except for the primary liver disease itself, those who have previously or currently suffered from other serious organ system diseases, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, tumor, immune, mental, or cardiovascular diseases or clinical laboratory examination abnormalities, which have clinical significance, and are determined by the research doctor to be unsuitable for participating in this trial;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
mild liver function impairment group
|
JT001 single dose, 0.3g
Other Names:
|
Experimental: Group B
moderate liver function impairment group
|
JT001 single dose, 0.3g
Other Names:
|
Experimental: Group C
normal liver function subject group
|
JT001 single dose, 0.3g
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Cmax of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
maximum observed plasma concentration
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
The AUC0-t of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
area under the curve from time zero to the last measurable concentration
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
The AUC0-inf of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
area under curve from time zero to infinity
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
Tmax of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
Time to maximum observed concentration of the main metabolite 116-N1 of JT001;
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
t1/2 of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
Terminal phase half-life of the main metabolite 116-N1 of JT001;
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
CL/F of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
The clearance of the main metabolite 116-N1 of JT001;
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
Vz/F of the main metabolite 116-N1 of JT001;
Time Frame: From time zero up to 72 hours post-dose following oral administration of JT001
|
The apparent volume of distribution of the main metabolite 116-N1 of JT001;
|
From time zero up to 72 hours post-dose following oral administration of JT001
|
The severity of SAE
Time Frame: From Day 1(first dose) to Day7
|
The severity of SAE
|
From Day 1(first dose) to Day7
|
The Number of participants with SAE
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with SAE
|
From Day 1(first dose) to Day7
|
The severity ofclinical symptoms abnormalities(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness)
Time Frame: From Day 1(first dose) to Day7
|
The severity ofclinical symptoms abnormalities(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness)
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal clinical symptoms(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness)
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal clinical symptoms(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness)
|
From Day 1(first dose) to Day7
|
The severity of vital signs abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of Pulse abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal vital signs
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal Pulse
|
From Day 1(first dose) to Day7
|
The severity of vital signs abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of blood pressure abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal vital signs
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal blood pressure
|
From Day 1(first dose) to Day7
|
The severity of vital signs abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of respiration abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal vital signs
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal respiration
|
From Day 1(first dose) to Day7
|
The severity of vital signs abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of body temperature abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal vital signs
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal body temperature
|
From Day 1(first dose) to Day7
|
The severity of abnormal physical examinations findings
Time Frame: From Day 1(first dose) to Day7
|
The severity of abnormal physical examinations findings
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal physical examinations findings
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal physical examinations findings
|
From Day 1(first dose) to Day7
|
The severity of abnormal laboratory tests results
Time Frame: From Day 1(first dose) to Day7
|
The severity of abnormal laboratory tests results
|
From Day 1(first dose) to Day7
|
The Number of participantswith abnormal laboratory tests results
Time Frame: From Day 1(first dose) to Day7
|
The Number of participantswith abnormal laboratory tests results
|
From Day 1(first dose) to Day7
|
The severity of electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of Heart rate abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with Heart rate abnormalities
|
From Day 1(first dose) to Day7
|
The severity of electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of PR interval abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with PR interval abnormalities
|
From Day 1(first dose) to Day7
|
The severity of electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of QRS interval abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with QRS interval abnormalities
|
From Day 1(first dose) to Day7
|
The severity of electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of QT interval abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with QT interval abnormalities
|
From Day 1(first dose) to Day7
|
The severity of electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The severity of QTcF abnormalities
|
From Day 1(first dose) to Day7
|
The Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: From Day 1(first dose) to Day7
|
The Number of participants with QTcF abnormalities
|
From Day 1(first dose) to Day7
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Huiyu Lan, Project Director, Shanghai Vinnerna Biosciences Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JT001-007-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subjects With Liver Function Injury
-
Jiangsu HengRui Medicine Co., Ltd.UnknownSubjects With Impaired Renal Function and Healthy Subjects
-
Rempex Pharmaceuticals (a wholly owned subsidiary...CompletedSubjects With Varying Degrees of Renal Insufficiency and | Subjects With Normal Renal FunctionUnited States
-
Asan Medical CenterRecruitingSubjects With Resectable and Localized Gastric Cancer | Subjects With Resectable Esophageal Cancer or Liver Cancer | Subjects With Resectable Liver CancerKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...TerminatedPK Properties Of Gabapentin In Subjects With Impaired Renal FunctionJapan
-
Yuhan CorporationRecruitingAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Yuhan CorporationCompletedAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Coloplast A/SCompletedSubjects With an IleostomyDenmark
-
Topcon Medical Systems, Inc.CompletedSubjects Presenting With Normal or With Ocular PathologyUnited States
-
Saladax Biomedical, Inc.Not yet recruitingSubjects Treated With Busulfan
-
Trisakti UniversityIndonesia University; Duke-NUS Graduate Medical School; BioGaia ABActive, not recruitingHealthy Subjects With Fixed OrthodonticsIndonesia
Clinical Trials on Deuremidevir Hydrobromide Tablets
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHCompletedHealthy Subjects | Subjects With Renal ImpairmentChina
-
Vigonvita Life SciencesCompleted
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHCompletedElderly Subjects With Underlying DiseasesChina
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionsChina
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
Shanghai Vinnerna Biosciences Co., Ltd.Active, not recruitingThe Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese SubjectsChina
-
Hartford HospitalSpero TherapeuticsCompletedDiabetes | ABSSSI | Healthy Volunteers | Wound InfectionUnited States
-
Spero TherapeuticsCompletedHealthy VolunteersUnited States
-
Spero TherapeuticsCompleted
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam